Merck & Co's Gardasil adds US indication for boys and men
This article was originally published in Scrip
Merck & Co's human papillomavirus vaccine Gardasil has extended its US label to include use in boys and men. On October 16th, the FDA approved a new indication in males aged nine to 26 years to prevent genital warts caused by HPV types 6 and 11.
You may also be interested in...
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.